--- title: "NextCure (NXTC) news: offering and merger" url: "https://aibio.space/companies/nextcure/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NXTC offering and merger news: NextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement. NextCure, Inc." --- NXTC NextCure, Inc. NASDAQ · United States # NextCure (NXTC) news NXTC offering and merger news Mergers · 2026-07-14 ## [NextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement](https://aibio.space/news/nextcure-signs-merger-agreement-avere-therapeutics-alongside-320/) NextCure (Nasdaq: NXTC) agreed to an all-stock merger with Avere Therapeutics. The 8-K puts pre-merger Avere holders at about 98.11% of the combined company, which would take the Avere Therapeutics name. ## Latest NextCure news 1. 2025-06-16 Financings [NextCure licenses SIM0505 for $12 million upfront, agrees to sell $2.0 million in stock](https://aibio.space/news/nextcure-licenses-sim0505-12-million-upfront-agrees-sell-2-0-million/) NextCure agreed to pay Hainan Simcere Zaiming $17 million, including a $12 million upfront payment, for rights to a Phase 1 antibody drug conjugate. A Zaiming affiliate agreed to buy 4,063,633 shares for $2.0 million, and the company now says its cash lasts into mid-2026, not the second half of 2026 that its March 6 annual report gave. ## NextCure at a glance - **Ticker**: NXTC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $15.3 million ### Related companies - [Electra Therapeutics](https://aibio.space/companies/electra-therapeutics/) NASDAQ: ETRA - [Soligenix](https://aibio.space/companies/soligenix/) NASDAQ: SNGX - [Capricor Therapeutics](https://aibio.space/companies/capricor-therapeutics/) NASDAQ: CAPR - [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) NASDAQ: VTVT - [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) NASDAQ: LTGO - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) NASDAQ: TARA ### Also on NASDAQ - [Anixa Biosciences](https://aibio.space/companies/anixa-biosciences/) ANIX - [Fortress Biotech](https://aibio.space/companies/fortress-biotech/) FBIO - [MAXCYTE, INC.](https://aibio.space/companies/maxcyte/) MXCT - [EyePoint](https://aibio.space/companies/eyepoint/) EYPT - [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) RNTX - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) ALDX ## What NextCure does NextCure, Inc. is a clinical-stage biopharmaceutical company focused on cancer patients whose disease does not respond to, or progresses on, current therapies. It advances targeted therapies, including antibody-drug conjugates (ADCs), which consist of a monoclonal antibody conjugated to a cytotoxic drug through a chemical linker. Its product candidate SIM0505 was licensed from Simcere Zaiming Pharmaceutical Co., Ltd., and is an ADC directed to cadherin-6 (CDH6) that carries a topoisomerase 1 inhibitor payload. Simcere Zaiming retains rights in China, Hong Kong, Macau and Taiwan. SIM0505 is in Phase 1 dose escalation studies in China for solid tumors, including ovarian, endometrial, non-small cell lung and renal cancers. The FDA cleared an Investigational New Drug application for a Phase 1 trial in December 2024, and the IND was assigned to NextCure in June 2025. The company announced dosing its first patient in October 2025 and expects to provide a Phase 1 dose escalation data readout in the second quarter of 2026. Its second product, LNCB74, is a B7-H4 targeted ADC designed to kill tumors, and preclinical studies demonstrated potent tumor killing and a favorable safety profile. | Product or program | What it is | Stage | |---|---|---| | SIM0505 | CDH6-directed ADC with topoisomerase 1 inhibitor payload for solid tumors | Phase 1 dose escalation (China); first US patient dosed October 2025 | | LNCB74 | B7-H4 targeted antibody-drug conjugate for tumors | | Summarised from the company's [10-K filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/nxtc-20251231x10k.htm). ## NextCure annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$44.9 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/) | [$41.5 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/) | | Net income (loss) | [-$55.8 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/) | [-$55.7 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/) | | Cash from operations | [-$49.6 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/) | [-$40.8 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/) | | Cash and equivalents | [$26.0 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926092050/) | [$27.7 million](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024137/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $15.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NextCure Has NextCure raised money recently? Our latest story on this, dated Jul 14, 2026: "NextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nextcure-signs-merger-agreement-avere-therapeutics-alongside-320/). Is NextCure involved in a merger or acquisition? Our latest story on this, dated Jul 14, 2026: "NextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nextcure-signs-merger-agreement-avere-therapeutics-alongside-320/). What is the ticker symbol of NextCure? NextCure, Inc. trades under the ticker NXTC on NASDAQ. Where is NextCure listed? NextCure, Inc. is listed on NASDAQ. What is the SEC CIK of NextCure? The SEC Central Index Key (CIK) for NextCure, Inc. is 1661059. Its filings are on SEC EDGAR. How many shares does NextCure have outstanding? 4,577,359 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is NextCure listed under? Our directory records NextCure, Inc. under United States. What does NextCure do? Our directory classifies NextCure, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of NextCure? The ISIN recorded for NextCure, Inc. is US65343E2072. Does aibio.space cover NextCure? aibio.space lists NextCure, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is NextCure incorporated? SEC records list its state or country of incorporation as DE. What does NextCure develop? NextCure, Inc. is a clinical-stage biopharmaceutical company focused on cancer patients whose disease does not respond to, or progresses on, current therapies. It advances targeted therapies, including antibody-drug conjugates (ADCs), which consist of a monoclonal antibody conjugated to a cytotoxic drug through a chemical linker. What is SIM0505 from NextCure? SIM0505: CDH6-directed ADC with topoisomerase 1 inhibitor payload for solid tumors Stage: Phase 1 dose escalation (China); first US patient dosed October 2025. What is LNCB74 from NextCure? LNCB74: B7-H4 targeted antibody-drug conjugate for tumors Stage: not stated in text. Is NextCure profitable? NextCure, Inc. reported a net loss of $55.8 million for the fiscal year ended Dec 31, 2025, and used $49.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: NextCure Members talk about NextCure (NXTC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NextCure, newest first. Each line links the filing it comes from. 1. 2026-09-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/nxtc-20260921xex99d1.htm) 2. 2026-07-14 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,5.01,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_ex99-1.htm) 3. 2026-07-14 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465926083327/tm2620428d1_8k.htm) 4. 2025-12-11 Financings Reported a financing. SEC Form 424B1. [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465925120346/tm2533262-1_424b1.htm) 5. 2025-11-17 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465925112975/nxtc-20251112xex99d1.htm) 6. 2025-08-07 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1661059/000155837025010782/nxtc-20250630x10q.htm) 7. 2025-07-18 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465925069012/tm2521171-1_s3.htm) 8. 2025-07-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000155837025009214/nxtc-20250714x8k.htm) 9. 2025-07-10 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000155837025009163/nxtc-20250710x8k.htm) 10. 2025-06-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000155837025008789/nxtc-20250620x8k.htm) 11. 2025-06-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000155837025008633/nxtc-20250613xex99d1.htm) 12. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465925038880/tm252402-4_def14a.htm) 13. 2025-04-15 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1661059/000110465925035118/tm252402-2_pre14aseq1.htm) 14. 2025-02-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1661059/000155837025000603/nxtc-20250131x8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NXTC on TradingView](https://www.tradingview.com/symbols/NASDAQ-NXTC/). ## SEC filings and registration - **SEC name**: NextCure, Inc. - **CIK**: 1661059 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NXTC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2850 QUARRY LAKE DRIVE, BALTIMORE, MD, 21209 - **Phone**: 240-399-4900 - **Shares outstanding**: 4,577,359 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/nxtc-20260921x8k.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1661059/000110465926105057/nxtc-20260903x8k.htm) filed 2026-09-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1661059/000110465926092050/nxtc-20260630x10q.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/nxtc-20260806x8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/tm2620428d1_8k.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1661059/000110465926077546/nxtc-20260618x8k.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/nxtc-20260601x8k.htm) filed 2026-06-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1661059/000110465926057187/nxtc-20260331x10q.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001661059), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NextCure, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NXTC, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NextCure, Inc. - **Ticker**: NXTC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US65343E2072 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NXTC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nextcure/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NextCure (NXTC) news: offering and merger", 2026-10-31, https://aibio.space/companies/nextcure/